Li Longhai, Zhang Lihua, Zhang Ting, Qi Xiaowei, Cheng Gang, Xia Lingxia
Department of Science and Education, The People's Hospital of Bozhou, Bozhou, China.
Department of Pathology, The Affiliated Hospital of Jiangnan University, Wuxi, China.
Front Oncol. 2021 Feb 10;10:599363. doi: 10.3389/fonc.2020.599363. eCollection 2020.
Due to the lack of typical symptoms and signs and sensitive indicators for early diagnosis of obstructive colorectal cancer (OCRC), it is critically needed to find new novel biomarkers to ameliorate the management of OCRC patients. In this study, 472 blood samples were collected and measured by enzyme-linked immunosorbent assay (ELISA) to investigate the value of serum chemokine ligand 7 (CXCL7) in diagnosis and prognosis for OCRC patients. The median concentrations of CXCL7 in non-OCRC and OCRC were both higher than that in controls (both < 0.05). Importantly, the median serum concentration of CXCL7 in OCRC was also higher than that in non-OCRC ( < 0.001). In all OCRC patients, the area under the curve (AUC) of CXCL7 was 0.918 with a sensitivity of 86.54% and a specificity of 81.87%. Similarly, the AUC of CXCL7 was 0.684 when the diagnostic test was performed between OCRC and CRC patients. CXCL7 had a higher AUC than other markers. The concentration of CXCL7 in 40 postoperative OCRC patients was higher than normal people and lower than preoperative patients. The median survival time was 62.00 months and the 5-year overall survival (OS) rate of the patients was 51.80% in all 155 OCRC patients. Multivariate Cox proportional hazard regression model analysis showed that high CXCL7 in serum was independent factors associated with poor OS of OCRC patients (HR = 2.216, = 0.032). These results demonstrate that serum CXCL7 may be a potential biomarker both in diagnosis and prognosis for OCRC patients.
由于缺乏典型症状、体征以及用于早期诊断阻塞性结直肠癌（OCRC）的敏感指标，因此迫切需要寻找新的生物标志物以改善OCRC患者的管理。在本研究中，收集了472份血样并通过酶联免疫吸附测定（ELISA）进行检测，以研究血清趋化因子配体7（CXCL7）在OCRC患者诊断和预后中的价值。非OCRC组和OCRC组中CXCL7的中位浓度均高于对照组（均P<0.05）。重要的是，OCRC组中血清CXCL7的中位浓度也高于非OCRC组（P<0.001）。在所有OCRC患者中，CXCL7的曲线下面积（AUC）为0.918，灵敏度为86.54%，特异性为81.87%。同样，在OCRC与结直肠癌（CRC）患者之间进行诊断测试时，CXCL7的AUC为0.684。CXCL7的AUC高于其他标志物。40例OCRC术后患者的CXCL7浓度高于正常人但低于术前患者。155例OCRC患者的中位生存时间为62.00个月，5年总生存率（OS）为51.80%。多因素Cox比例风险回归模型分析显示，血清中高CXCL7是与OCRC患者OS不良相关的独立因素（HR=2.216，P=0.032）。这些结果表明，血清CXCL7可能是OCRC患者诊断和预后的潜在生物标志物。
